On Tuesday, Boehringer Ingelheim’s Empagliflozin became off-patent in India. Major domestic drugmakers are expected to launch their generic versions soon. According to the company’s statement ...

(Image Credits: Pixabay) Boehringer Ingelheim’s blockbuster diabetes drug, Empagliflozin, is now off-patent in India, paving the way for domestic drugmakers to launch generic versions.

Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseases "Together with Veeva, Boehringer has advanced its approach to clinical ...

Some media reports have been oversimplistically juxtaposing the two decisions, either lamenting or celebrating the Christian character as a repudiation of the trans one, when of course ...

Boehringer Ingelheim GmbH terminated its second metabolic dysfunction-associated steatohepatitis (MASH) alliance on March 6, ending an $870 million license agreement inked with Yuhan Corp. for dual ...